Welcome back,

Tag : mFOLFOX6

CONFERENCE UPDATE

Encorafenib + cetuximab + chemotherapy improves PFS and OS as first-line therapy in BRAF V600E-mutant mCRC: Results from the phase 3 BREAKWATER trial
The BREAKWATER trial shows that encorafenib, cetuximab, and chemotherapy significantly improve PFS and overall survival in BRAF V600E-mutant metastatic colorectal cancer (mCRC) patients. This promising first-line treatment could reshape standard care protocols for this challenging subgroup.